RTP Mobile Logo
Patterns of Care: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Edition, Issue 1, 2011
Released March 2011

Survey of 100 Practicing Medical Oncologists and 25 Clinical Investigators on Issues Related to the Treatment of Seven Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Presented by Contributing Faculty Members Drs Jonathan W Friedberg and Mitchell R Smith. (Text Content)

CE Disclosures and Faculty Information

  • CME credit is no longer available for this issue

    OVERVIEW OF ACTIVITY


    It is important for medical oncologists, hematologists and fellows to be aware of similarities and differences among their patterns of cancer care and those of other community practitioners and non-Hodgkin lymphoma (NHL) clinical investigators. Additionally, the recognition that heterogeneity exists within the treating oncology community underscores the existence of clinical situations for which the research evidence to support a single definitive approach may be suboptimal.

    This program focuses on the self-described treatment approaches used by randomly selected community medical oncologists and hematologists in a variety of key clinical scenarios in NHL. Also included are the parallel treatment approaches used by clinical investigators in academic practices, commentary from lymphoma experts and references addressing these topics. This CME program will provide medical oncologists, hematologists and hematology-oncology fellows with information on national cancer patterns of care to assist with the development of best-practice clinical management strategies for NHL.

    LEARNING OBJECTIVES

     

    • Compare treatment strategies employed by community oncologists and cancer clinical investigators, and apply this knowledge to the routine management of NHL, including chronic lymphocytic leukemia.
    • Evaluate clinical issues for which relative agreement and heterogeneity exist in patterns of NHL care, and make treatment decisions considering this information.
    • Counsel patients with diverse subtypes of NHL about the benefits and risks of multiple acceptable treatment options when they exist.
    • Summarize common toxicities associated with the systemic treatment of NHL, and identify current approaches to reduce or ameliorate these side effects.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT


    Research To Practice designates this educational activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains a print component. To receive credit, the participant should read the text portion and complete the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/POCNHL110/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FriedbergAdvisory Committee: Genentech BioOncology; Consulting Agreements: Allos Therapeutics, Astellas Pharma US Inc, Calistoga Pharmaceuticals Inc, EMD Serono Inc, Seattle Genetics; Data Safety Monitoring Board: Lilly USA LLC; Research Support: Cephalon Inc, Millennium — The Takeda Oncology Company; Stock Ownership: Bristol-Myers Squibb Company. Dr SmithAdvisory Committee: Cephalon Inc, Wyeth; Speakers Bureau: Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Millennium — The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    CME DISCLOSURES FOR QUOTED FACULTY

    Dr Cheson
    Advisory Committee: Allos Therapeutics, Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Millennium — The Takeda Oncology Company; Consulting Agreement: Millennium — The Takeda Oncology Company. Dr FisherConsulting Agreements: Millennium — The Takeda Oncology Company, Pfizer Inc, Roche Laboratories Inc. Dr FossAdvisory Committee: Allos Therapeutics; Speakers Bureau: Allos Therapeutics, Celgene Corporation, Eisai Inc. Dr GregoryAdvisory Committee: Cephalon Inc; Consulting Agreements: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; Speakers Bureau: Cephalon Inc, Genentech BioOncology. Dr HorwitzConsulting Agreements: Allos Therapeutics, Celgene Corporation, Millennium — The Takeda Oncology Company; Paid Research: Allos Therapeutics, Genzyme Corporation. Dr KahlAdvisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology; Consulting Agreements: Celgene Corporation, Roche Laboratories Inc. Dr KantarjianPaid Research: Bristol-Myers Squibb Company, Genzyme Corporation, Novartis Pharmaceuticals Corporation. Dr LeonardConsulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis. Dr McLaughlinAdvisory Committee: Celgene Corporation, Genentech BioOncology, Seattle Genetics; Speakers Bureau: Spectrum Pharmaceuticals Inc. Dr RummelAdvisory Committee: Amgen Inc, Cephalon Inc, GlaxoSmithKline. Dr YounesAdvisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmion Corporation, Roche Laboratories Inc, Sanofi-Aventis. Dr ZelenetzPaid Research: Amgen Inc, Cell Therapeutics Inc, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis, Spectrum Pharmaceuticals Inc and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    Contributing Editors

    Jonathan W Friedberg, MD, MMSc
    Associate Professor of
    Medicine and Hematology
    Chief, Hematology/Oncology Division
    James P Wilmot Cancer Center
    University of Rochester
    Rochester, New York

    Mitchell R Smith, MD, PhD
    Director, Lymphoma Service
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Clinical Investigators Completing the Survey

    Ranjana Advani, MD
    Associate Professor Medicine
    Division of Oncology
    Stanford University Medical Center
    Stanford, California

    Philippe Armand, MD, PhD
    Assistant Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Steven H Bernstein, MD
    Professor of Medicine
    James P Wilmot Cancer Center
    University of Rochester
    Rochester, New York

    Fernando Cabanillas, MD
    Clinical Professor of Medicine
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas
    Medical Director
    Auxilio Mutuo Cancer Center
    San Juan, Puerto Rico

    Bruce D Cheson, MD
    Professor of Medicine; Head of Hematology
    Director of Hematology Research
    Georgetown University Hospital
    Lombardi Comprehensive Cancer Center
    Washington, DC

    Myron S Czuczman, MD
    Head, Lymphoma/Myeloma Service
    Head, Lymphoma Translational Research Laboratory
    Roswell Park Cancer Institute
    Professor of Medicine
    School of Medicine and Biomedical Sciences
    State University of New York at Buffalo
    Buffalo, New York
     
    Edward A Faber Jr, DO, MS
    Assistant Professor
    Division of Oncology/Hematology
    University of Nebraska Medical Center
    Omaha, Nebraska
     
    Richard I Fisher, MD
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Center
    Director, University of Rochester Medical Faculty Group
    Senior Associate Dean for Clinical Affairs
    Vice President, University of Rochester Medical Center
    Rochester, New York

    Nathan H Fowler, MD
    Department of Lymphoma/Myeloma
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Ajay K Gopal, MD
    Associate Professor
    Division of Medical Oncology
    University of Washington
    Associate Member, Fred Hutchinson Cancer Research Center
    Clinical Research Director, Hematologic Malignancies and Hematology
    Seattle Cancer Care Alliance
    Seattle, Washington

    Stephanie A Gregory, MD
    The Elodia Kehm Chair of Hematology
    Professor of Medicine
    Director, Section of Hematology
    Rush University Medical Center/
    Rush University
    Chicago, Illinois

    Fredrick B Hagemeister, MD
    Professor of Medicine
    The University of Texas
    MD Anderson Cancer Center
    Department of Lymphoma/Myeloma
    Houston, Texas

    Paul A Hamlin, MD

    Assistant Member and Attending Physician
    Lymphoma Service
    Division of Hematologic Oncology
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Francisco J Hernandez-Ilizaliturri, MD
    Assistant Professor of Medical Oncology and Immunology
    Departments of Medical Oncology and Immunology
    Cancer Cell Center
    Roswell Park Cancer Institute
    Buffalo, New York

    Steven M Horwitz, MD
    Assistant Attending, Lymphoma Service
    Division of Hematologic Oncology
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    John P Leonard, MD
    Richard T Silver Distinguished Professor
    of Hematology and Medical Oncology
    Professor of Medicine, Weill Cornell Medical College
    Associate Director for Clinical Research, Weill Cornell Cancer Center
    Clinical Director, Center for Lymphoma and Myeloma
    Attending Physician, NewYork-Presbyterian Hospital
    New York, New York

    David G Maloney, MD, PhD

    Member, Clinical Research Division
    Fred Hutchinson Cancer Research Center
    Professor of Medicine, Division of Oncology
    University of Washington
    Seattle, Washington

    Matthew J Matasar, MD, MS
    Attending Physician, Lymphoma and Adult Stem Cell Transplant Services
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Vicki A Morrison, MD
    Professor of Medicine
    University of Minnesota
    Staff Physician, Hematology/Oncology and Infectious Disease
    VA Medical Center
    Minneapolis, Minnesota

    Craig Moskowitz, MD
    Clinical Director, Division of Hematologic Oncology
    Member, Lymphoma Service
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Pierluigi Porcu, MD
    Associate Professor of Internal Medicine
    Division of Hematology-Oncology
    Comprehensive Cancer Center
    The Ohio State University
    Columbus, Ohio

    Oliver W Press, MD, PhD
    Member, Fred Hutchinson Cancer Research Center
    Recipient, Dr Penny E Petersen Memorial Chair for Lymphoma Research
    Professor of Medicine, University of Washington
    Seattle, Washington

    Julie M Vose, MD
    Neumann M and Mildred E Harris Professor
    Chief, Section of Hematology/Oncology
    Professor of Medicine
    Nebraska Medical Center
    Omaha, Nebraska

    This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2011
    Expiration date: March 2012

    CME credit is no longer available for this issue

Acknowledge and close

Read print: